Correlation Between Milestone Pharmaceuticals and Scopus Biopharma

Can any of the company-specific risk be diversified away by investing in both Milestone Pharmaceuticals and Scopus Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Milestone Pharmaceuticals and Scopus Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Milestone Pharmaceuticals and Scopus Biopharma, you can compare the effects of market volatilities on Milestone Pharmaceuticals and Scopus Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Milestone Pharmaceuticals with a short position of Scopus Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Milestone Pharmaceuticals and Scopus Biopharma.

Diversification Opportunities for Milestone Pharmaceuticals and Scopus Biopharma

0.0

Correlation Coefficient

Milestone Pharmaceuticals  Scopus Biopharma

Pay attention - limited upside

The 3 months correlation between Milestone and Scopus is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Milestone Pharmaceuticals and Scopus Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scopus Biopharma and Milestone Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Milestone Pharmaceuticals are associated (or correlated) with Scopus Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scopus Biopharma has no effect on the direction of Milestone Pharmaceuticals i.e., Milestone Pharmaceuticals and Scopus Biopharma go up and down completely randomly.

Pair Corralation between Milestone Pharmaceuticals and Scopus Biopharma

Given the investment horizon of 90 days Milestone Pharmaceuticals is expected to generate 0.28 times more return on investment than Scopus Biopharma. However, Milestone Pharmaceuticals is 3.55 times less risky than Scopus Biopharma. It trades about 0.0 of its potential returns per unit of risk. Scopus Biopharma is currently generating about -0.01 per unit of risk. If you would invest  379.00  in Milestone Pharmaceuticals on October 11, 2024 and sell it today you would lose (159.00) from holding Milestone Pharmaceuticals or give up 41.95% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	2.82%
Values	Daily Returns

Milestone Pharmaceuticals  vs.  Scopus Biopharma

Milestone Pharmaceuticals

Risk-Adjusted Performance

15 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Milestone Pharmaceuticals are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Milestone Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Scopus Biopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Scopus Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Scopus Biopharma is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Milestone Pharmaceuticals and Scopus Biopharma

The main advantage of trading using opposite Milestone Pharmaceuticals and Scopus Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Milestone Pharmaceuticals position performs unexpectedly, Scopus Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scopus Biopharma will offset losses from the drop in Scopus Biopharma's long position.

The idea behind Milestone Pharmaceuticals and Scopus Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.